Average Co-Inventor Count = 6.48
ph-index = 12
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Amgen Fremont Inc. (17 from 78 patents)
2. Medimmune Limited (10 from 541 patents)
3. Innovative Targeting Solutions Inc. (6 from 6 patents)
4. Amgen Inc. (4 from 1,976 patents)
5. Abbott Laboratories Corporation (2 from 4,179 patents)
6. Psma Development Company, LLC (2 from 5 patents)
7. Astrazeneca Ab (1 from 1,501 patents)
8. Dendreon Corporation (1 from 53 patents)
9. Medlmmune Limited (6 patents)
40 patents:
1. 11518809 - Targeted binding agents against B7-H1
2. 11492411 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
3. 10563206 - Generating targeted sequence diversity in fusion proteins
4. 10508153 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
5. 10400039 - Targeted binding agents against B7-H1
6. 10233453 - Generating targeted sequence diversity in fusion proteins
7. 10118968 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
8. 9914929 - Generating targeted sequence diversity in fusion proteins
9. 9718871 - Generating targeted sequence diversity in proteins
10. 9493565 - Targeted binding agents against B7-H1
11. 9096672 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
12. 9085624 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
13. 9073998 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
14. 9062113 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
15. 8858942 - Antibodies directed to ERBB2